FORT MYERS — Cancer-testing laboratory NeoGenomics recently filed a registration statement with securities regulators to raise as much as $25 million.
In a filing with the Securities and Exchange Commission, NeoGenomics says it plans to raise the capital by selling common stock, preferred stock or warrants. The filing is a so-called “shelf registration,” which means the company plans to raise the capital with equity or debt in the undisclosed future.
In addition, the filing says a single shareholder plans to sell 300,000 shares of NeoGenomics stock. The seller is Mary S. Dent Gifting Trust and those shares will be sold in the open market. Mary Dent is the spouse of NeoGenomics Founder Michael Dent.
The shares of NeoGenomics recently began trading on the Nasdaq Capital Market, boosting its exposure to institutional investors. The shares now trade under the symbol NEO (recent price: $2.85).